We are live on ! Find out more
RJFSA

Raymond James Financial Services Advisors Portfolio holdings

AUM $75.1B
1-Year Est. Return 31.89%
This Fund
S&P 500
This Quarter Est. Return
+10.61%
1 Year Est. Return
+31.89%
3 Year Est. Return
+38.17%
5 Year Est. Return
+106.56%
10 Year Est. Return
+236.84%
AUM
$61.5B
AUM Growth
+$6.37B
Cap. Flow
+$856M
Cap. Flow %
1.39%
Top 10 Hldgs %
16.58%
Holding
3,487
New
224
Increased
1,415
Reduced
1,546
Closed
198

Sector Composition

Rank Sector Weight
1 Technology 12.32%
2 Financials 6.7%
3 Healthcare 5.37%
4 Consumer Discretionary 5.01%
5 Industrials 4.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VAXX
3226
DELISTED
Vaxxinity, Inc. Class A Common Stock
VAXX
$15.7K ﹤0.01%
18,495
-164
-0.9% -$158
BHIL
3227
DELISTED
Benson Hill, Inc.
BHIL
$13.9K ﹤0.01%
+2,286
New +$20.4K
RENT
3228
Rent the Runway
RENT
$122M
$13.3K ﹤0.01%
+1,257
New +$15.5K
OCGN icon
3229
Ocugen
OCGN
$454M
$13.2K ﹤0.01%
22,923
+3,680
+19% +$1.48K
OESX icon
3230
Orion Energy Systems
OESX
$79.5M
$12.8K ﹤0.01%
1,480
GWH icon
3231
ESS Tech
GWH
$19.4M
$12.8K ﹤0.01%
748
SHCR
3232
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
$12.4K ﹤0.01%
+11,500
New +$11.8K
VGZ icon
3233
Vista Gold
VGZ
$328M
$11.2K ﹤0.01%
+24,866
New +$9.26K
NKTR icon
3234
Nektar Therapeutics
NKTR
$2.57B
$11K ﹤0.01%
+1,293
New +$9.79K
INSG icon
3235
Inseego
INSG
$77.8M
$10.4K ﹤0.01%
4,716
-696
-13% -$2.1K
NVTA
3236
DELISTED
Invitae Corporation
NVTA
$10.3K ﹤0.01%
16,482
-5,300
-24% -$3.17K
ATOS icon
3237
Atossa Therapeutics
ATOS
$25.5M
$9.52K ﹤0.01%
721
-81
-10% -$874
GOEV
3238
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$9.03K ﹤0.01%
76
+17
+29% +$2.3K
SGMO
3239
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.82K ﹤0.01%
16,239
-9,393
-37% -$4.33K
DARE icon
3240
Dare Bioscience
DARE
$20.5M
$8.53K ﹤0.01%
2,299
+632
+38% +$2.89K
CTXR icon
3241
Citius Pharmaceuticals
CTXR
$20.2M
$8.4K ﹤0.01%
444
DCFC
3242
DELISTED
Tritium DCFC Limited Ordinary Shares
DCFC
$8.11K ﹤0.01%
184
-5
-3% -$237
INUV icon
3243
Inuvo
INUV
$14.3M
$7.65K ﹤0.01%
1,800
CATX icon
3244
Perspective Therapeutics
CATX
$354M
$7.04K ﹤0.01%
1,750
GMDA
3245
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$6.69K ﹤0.01%
16,204
AKLI
3246
DELISTED
Akili Inc
AKLI
$6.06K ﹤0.01%
12,448
KSCP icon
3247
Knightscope
KSCP
$32.4M
$6.03K ﹤0.01%
+201
New +$7.02K
ASXC
3248
DELISTED
Asensus Surgical, Inc.
ASXC
$4.51K ﹤0.01%
14,143
+110
+0.8% +$28
WKHS icon
3249
Workhorse Group
WKHS
$33.3M
$3.94K ﹤0.01%
4
MP icon
3250
CALL
MP Materials
MP
$9.91B
$3.5K ﹤0.01%
100

Similar funds

Raymond James Financial Services Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Raymond James Financial Services Advisors held 3,487 positions worth $61.5B, up 12% from $55.2B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Raymond James Financial Services Advisors's Q4 2023 filing shows 224 new, 1,415 increased, 1,546 reduced and 198 closed positions. Its largest new stake was iShares MSCI Poland ETF: 1,070,303 shares worth $24.2M. The largest sale was Vanguard S&P 500 ETF, an estimated $154M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 12% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James Financial Services Advisors's largest Q4 2023 buy was iShares MSCI Poland ETF: 1,070,303 shares worth $24.2M.
  • Raymond James Financial Services Advisors added most to Diamondback Energy in Q4 2023, an estimated $69.2M increase.
  • Raymond James Financial Services Advisors's biggest Q4 2023 reduction was Vanguard S&P 500 ETF, cutting an estimated $154M.
  • Raymond James Financial Services Advisors fully exited iShares iBonds Dec 2023 Term Corporate ETF in Q4 2023, selling an estimated $28.2M.
  • Raymond James Financial Services Advisors's ten largest holdings make up 17% of its $61.5B portfolio in Q4 2023.
  • Raymond James Financial Services Advisors opened 224 new positions and closed 198 in Q4 2023.
  • Raymond James Financial Services Advisors's portfolio value rose 12% quarter-over-quarter to $61.5B.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.